Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12361968 | 0.84 | DGAT1 (0.39) | CNR2DGAT1ALDH1A1NPSR1 | |
| SCHEMBL6371782 | 0.82 | PKM (0.42) | ALDH1A1SMN1; SMN2KDM4EMEN1MAPT | |
| SCHEMBL20671829 | 0.80 | DGAT1 (0.37) | CNR2DGAT1ALDH1A1NPSR1MEN1 | |
| SCHEMBL32683939 | 0.78 | MGAM (0.41) | CNR2DGAT1NPSR1MEN1KMT2A | |
| SCHEMBL14902200 | 0.78 | MGAM (0.41) | CNR2DGAT1ALDH1A1NPSR1MEN1 | |
| SCHEMBL2858623 | 0.77 | KDM4C (0.50) | ALDH1A1SMN1; SMN2EGFRKDM4EMAPT | |
| SCHEMBL10042967 | 0.77 | DGAT1 (0.34) | CNR2DGAT1NPSR1 | |
| SCHEMBL8826965 | 0.76 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2EGFRKDM4EMEN1 | |
| SCHEMBL3688558 | 0.75 | ALDH1A1 (0.33) | CNR2DGAT1ALDH1A1NPSR1KDM4E | |
| SCHEMBL263784 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2629607-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NovaBay Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| CN-103260402-A | Antimicrobial polyether and polyol compounds | NOVABAY PHARMACEUTICALS INC | 2013-08-21 | — | — | CN | disclosed |
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | NOVABAY PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | NOVABAY PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2012054521-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NOVABAY PHARMACEUTICLAS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CNR2 204/4885DGAT1 3016/4885ALDH1A1 1443/4885 |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | POLR1C, DPM1, PRF1 | CNR2 4823/4885DGAT1 210/4885ALDH1A1 1198/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CNR2 204/4885DGAT1 3016/4885ALDH1A1 1443/4885 |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | CNR2 3163/4885DGAT1 448/4885ALDH1A1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.